Press Room

News / Dec 05, 2021

Hovione Cork renews its certification of The Business Working Responsibly Mark

A recognition for CSR practices at the site and its positive impact on both the workplace and the wider community

Hovione wins business working responsibility mark

Recently the Hovione Cork site achieved certification of The Business Working Responsibly Mark for the second time, having first achieved the Mark in 2018. The Mark is the leading independently audited standard for Corporate Social Responsibility (CSR) and Sustainability certification in Ireland and is based on ISO26000. The Mark assessment process involved a root to branch review of Hovione's corporate social responsibility and sustainability management systems across five pillars - Governance, Workplace, Marketplace, Environment and Community.

 

“The awarding of the certification for another 3 years is great recognition of the work and dedication that the team in Cork have to continuously improving and developing the CSR standards and practices at the site and its positive impact on both the workplace and the wider community”, said Louise Dennehy.

Business Working Responsibility Mark logo | Hovione

























 

The process for recertification began in April this year lead by Louise Dennehy, HR Business Partner, Marguerite Lynch, HSE Manager - Environment, Bruno Dias, OpEx Specialist and Maureen O'Leary, Procurement Manager with the audit taking place virtually at the end of October. Along with a full process and documentation review, 4 team members were interviewed by the assessor on their knowledge, awareness and understanding of the company’s CSR activities.

 

You might be also interested in:









 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026